Liquidia (NASDAQ:LQDA) Insider Sarah Krepp Sells 24,880 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 24,880 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $70.28, for a total value of $1,748,566.40. Following the sale, the insider directly owned 121,863 shares of the company’s stock, valued at approximately $8,564,531.64. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Krepp also recently made the following trade(s):

• On Monday, June 1st, Sarah Krepp sold 276 shares of Liquidia stock. The shares were sold at an average price of $60.87, for a total value of $16,800.12.
• On Monday, April 13th, Sarah Krepp sold 4,557 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total value of $174,852.09.

Liquidia Stock Up 0.8%

Shares of NASDAQ:LQDA opened at $71.80 on Tuesday. The company has a market capitalization of $6.39 billion, a price-to-earnings ratio of 512.89 and a beta of 0.57. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $72.71. The business has a 50-day moving average price of $50.54 and a 200 day moving average price of $41.24. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s revenue was up 4187.1% compared to the same quarter last year. Sell-side analysts expect that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the 4th quarter valued at $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia during the second quarter worth $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia during the third quarter worth $30,000. FNY Investment Advisers LLC purchased a new position in Liquidia in the third quarter valued at $34,000. Finally, Covestor Ltd raised its stake in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on LQDA shares. Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Raymond James Financial restated a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Finally, Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $60.29.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).